How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?

F. M. Wagner, H. Reichenspurner, P. Uberfuhr, F. Kur, H. G. Kaulbach, B. M. Meiser, U. Ziegler, B. Reichart, William A Baumgartner, G. Massard, K. Brinker, S. L. Olsen, A. Keogh, U. Livi, S. Hunt

Research output: Contribution to journalArticle

Abstract

OKT3 is recommended as rescue therapy for cases of steroid-resistant, clinically persistant acute rejection episodes after heart transplantation. In this study we determined the efficacy of such treatment. One hundred thirty-two patients were included in this study. The postoperative immunosuppressive regimen consisted of triple-drug therapy and perioperative antithymocyte globulin. During a follow-up of 10 to 108 weeks (mean, 51 ± 20 weeks) 281 treatment-requiring acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) were observed. In 29 cases (10.3%) the grade of the acute rejection episodes was either unchanged after two series of intravenous steroid pulse therapy, was worsened after the first steroid course, or the patient experienced clinical deterioration as a result of the acute rejection episodes. These patients were considered to have steroid-resistant acute rejection episodes and received a 10-day rescue therapy with OKT3, followed by control endomyocardial biopsy. In 17 cases, control endomyocardial biopsy revealed normal myocardium (group I). In 10 cases acute rejection episodes remained unchanged (group II); twice a deterioration was found (group III). However, 12 of the 17 patients from group I experienced a rebound of the acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) 1 to 3 weeks later. Side effects of OKT3 treatment were fever, chills, intestinal complications, hemodynamic response, convulsions, and viral infections. Complete remission of steroid-resistant acute rejection episodes by OKT3 rescue therapy was therefore only achieved in five patients (17.2%), in all other cases further treatment of the acute rejection episodes with methotrexate was necessary. As a result from this study routine OKT3 rescue therapy has been discontinued at our center and remains restricted to particular cases.

Original languageEnglish (US)
Pages (from-to)438-443
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume13
Issue number3
StatePublished - Jun 13 1994
Externally publishedYes

Fingerprint

Muromonab-CD3
Heart Transplantation
Steroids
Therapeutics
Biopsy
Chills
Antilymphocyte Serum
Virus Diseases
Immunosuppressive Agents
Methotrexate
Myocardium
Seizures
Fever
Hemodynamics
Drug Therapy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Wagner, F. M., Reichenspurner, H., Uberfuhr, P., Kur, F., Kaulbach, H. G., Meiser, B. M., ... Hunt, S. (1994). How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? Journal of Heart and Lung Transplantation, 13(3), 438-443.

How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? / Wagner, F. M.; Reichenspurner, H.; Uberfuhr, P.; Kur, F.; Kaulbach, H. G.; Meiser, B. M.; Ziegler, U.; Reichart, B.; Baumgartner, William A; Massard, G.; Brinker, K.; Olsen, S. L.; Keogh, A.; Livi, U.; Hunt, S.

In: Journal of Heart and Lung Transplantation, Vol. 13, No. 3, 13.06.1994, p. 438-443.

Research output: Contribution to journalArticle

Wagner, FM, Reichenspurner, H, Uberfuhr, P, Kur, F, Kaulbach, HG, Meiser, BM, Ziegler, U, Reichart, B, Baumgartner, WA, Massard, G, Brinker, K, Olsen, SL, Keogh, A, Livi, U & Hunt, S 1994, 'How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?', Journal of Heart and Lung Transplantation, vol. 13, no. 3, pp. 438-443.
Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM et al. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? Journal of Heart and Lung Transplantation. 1994 Jun 13;13(3):438-443.
Wagner, F. M. ; Reichenspurner, H. ; Uberfuhr, P. ; Kur, F. ; Kaulbach, H. G. ; Meiser, B. M. ; Ziegler, U. ; Reichart, B. ; Baumgartner, William A ; Massard, G. ; Brinker, K. ; Olsen, S. L. ; Keogh, A. ; Livi, U. ; Hunt, S. / How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?. In: Journal of Heart and Lung Transplantation. 1994 ; Vol. 13, No. 3. pp. 438-443.
@article{316c5d8098c54ffab7c09da5c1a34979,
title = "How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?",
abstract = "OKT3 is recommended as rescue therapy for cases of steroid-resistant, clinically persistant acute rejection episodes after heart transplantation. In this study we determined the efficacy of such treatment. One hundred thirty-two patients were included in this study. The postoperative immunosuppressive regimen consisted of triple-drug therapy and perioperative antithymocyte globulin. During a follow-up of 10 to 108 weeks (mean, 51 ± 20 weeks) 281 treatment-requiring acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) were observed. In 29 cases (10.3{\%}) the grade of the acute rejection episodes was either unchanged after two series of intravenous steroid pulse therapy, was worsened after the first steroid course, or the patient experienced clinical deterioration as a result of the acute rejection episodes. These patients were considered to have steroid-resistant acute rejection episodes and received a 10-day rescue therapy with OKT3, followed by control endomyocardial biopsy. In 17 cases, control endomyocardial biopsy revealed normal myocardium (group I). In 10 cases acute rejection episodes remained unchanged (group II); twice a deterioration was found (group III). However, 12 of the 17 patients from group I experienced a rebound of the acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) 1 to 3 weeks later. Side effects of OKT3 treatment were fever, chills, intestinal complications, hemodynamic response, convulsions, and viral infections. Complete remission of steroid-resistant acute rejection episodes by OKT3 rescue therapy was therefore only achieved in five patients (17.2{\%}), in all other cases further treatment of the acute rejection episodes with methotrexate was necessary. As a result from this study routine OKT3 rescue therapy has been discontinued at our center and remains restricted to particular cases.",
author = "Wagner, {F. M.} and H. Reichenspurner and P. Uberfuhr and F. Kur and Kaulbach, {H. G.} and Meiser, {B. M.} and U. Ziegler and B. Reichart and Baumgartner, {William A} and G. Massard and K. Brinker and Olsen, {S. L.} and A. Keogh and U. Livi and S. Hunt",
year = "1994",
month = "6",
day = "13",
language = "English (US)",
volume = "13",
pages = "438--443",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?

AU - Wagner, F. M.

AU - Reichenspurner, H.

AU - Uberfuhr, P.

AU - Kur, F.

AU - Kaulbach, H. G.

AU - Meiser, B. M.

AU - Ziegler, U.

AU - Reichart, B.

AU - Baumgartner, William A

AU - Massard, G.

AU - Brinker, K.

AU - Olsen, S. L.

AU - Keogh, A.

AU - Livi, U.

AU - Hunt, S.

PY - 1994/6/13

Y1 - 1994/6/13

N2 - OKT3 is recommended as rescue therapy for cases of steroid-resistant, clinically persistant acute rejection episodes after heart transplantation. In this study we determined the efficacy of such treatment. One hundred thirty-two patients were included in this study. The postoperative immunosuppressive regimen consisted of triple-drug therapy and perioperative antithymocyte globulin. During a follow-up of 10 to 108 weeks (mean, 51 ± 20 weeks) 281 treatment-requiring acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) were observed. In 29 cases (10.3%) the grade of the acute rejection episodes was either unchanged after two series of intravenous steroid pulse therapy, was worsened after the first steroid course, or the patient experienced clinical deterioration as a result of the acute rejection episodes. These patients were considered to have steroid-resistant acute rejection episodes and received a 10-day rescue therapy with OKT3, followed by control endomyocardial biopsy. In 17 cases, control endomyocardial biopsy revealed normal myocardium (group I). In 10 cases acute rejection episodes remained unchanged (group II); twice a deterioration was found (group III). However, 12 of the 17 patients from group I experienced a rebound of the acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) 1 to 3 weeks later. Side effects of OKT3 treatment were fever, chills, intestinal complications, hemodynamic response, convulsions, and viral infections. Complete remission of steroid-resistant acute rejection episodes by OKT3 rescue therapy was therefore only achieved in five patients (17.2%), in all other cases further treatment of the acute rejection episodes with methotrexate was necessary. As a result from this study routine OKT3 rescue therapy has been discontinued at our center and remains restricted to particular cases.

AB - OKT3 is recommended as rescue therapy for cases of steroid-resistant, clinically persistant acute rejection episodes after heart transplantation. In this study we determined the efficacy of such treatment. One hundred thirty-two patients were included in this study. The postoperative immunosuppressive regimen consisted of triple-drug therapy and perioperative antithymocyte globulin. During a follow-up of 10 to 108 weeks (mean, 51 ± 20 weeks) 281 treatment-requiring acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) were observed. In 29 cases (10.3%) the grade of the acute rejection episodes was either unchanged after two series of intravenous steroid pulse therapy, was worsened after the first steroid course, or the patient experienced clinical deterioration as a result of the acute rejection episodes. These patients were considered to have steroid-resistant acute rejection episodes and received a 10-day rescue therapy with OKT3, followed by control endomyocardial biopsy. In 17 cases, control endomyocardial biopsy revealed normal myocardium (group I). In 10 cases acute rejection episodes remained unchanged (group II); twice a deterioration was found (group III). However, 12 of the 17 patients from group I experienced a rebound of the acute rejection episodes (International Society for Heart and Lung Transplantation ≥ II) 1 to 3 weeks later. Side effects of OKT3 treatment were fever, chills, intestinal complications, hemodynamic response, convulsions, and viral infections. Complete remission of steroid-resistant acute rejection episodes by OKT3 rescue therapy was therefore only achieved in five patients (17.2%), in all other cases further treatment of the acute rejection episodes with methotrexate was necessary. As a result from this study routine OKT3 rescue therapy has been discontinued at our center and remains restricted to particular cases.

UR - http://www.scopus.com/inward/record.url?scp=0028307359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028307359&partnerID=8YFLogxK

M3 - Article

C2 - 8061020

AN - SCOPUS:0028307359

VL - 13

SP - 438

EP - 443

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 3

ER -